Humanin is a short peptide encoded in mitochondrial DNA, the small set of genes found inside mitochondria. It is not FDA-approved, no approved medicine in the United States contains it, and human research has so far been limited to measuring its natural levels in the body.
Humanin belongs to a group called mitochondrial-derived peptides, which also includes MOTS-c.
Humanin was first described in 2001 by researchers in Japan, in a paper by Yuichi Hashimoto and colleagues in the journal PNAS. They screened genes from the brain tissue of a person with Alzheimer's disease, looking for any that protected nerve cells in the laboratory. The gene they found, which they named humanin, protected cultured nerve cells from death caused by Alzheimer's-related genes and by amyloid-beta, the protein that builds up in the disease. They also found that cells released the peptide into the surrounding fluid, and that its protective effect depended on its exact amino acid sequence.
Since then, humanin and synthetic variants made in the laboratory have been studied in cell and animal experiments on cell stress, metabolism and aging.
Human research has been observational. Studies have measured humanin levels in blood or tissue, for example in people having heart surgery or with acute kidney injury, to see whether levels relate to health outcomes. As of September 2026, ClinicalTrials.gov listed no trials testing humanin or its variants as a treatment.
Findings in cells, animals and blood-level studies do not show that taking humanin is safe or useful for people.
Current status: Not FDA-approved.
Humanin has not gone through the FDA review that a drug must pass before it can be marketed for use in people. There is no FDA-approved product that contains it. It does not appear in any category of the FDA's 503A nomination lists (as updated May 14, 2026) and is not on the 503A bulks list, so it does not meet the conditions for 503A compounding.
Humanin and its synthetic variants remain research compounds, not medicines, and they are not dietary supplements. Products labeled "for research purposes only" or "not for human consumption" are not approved medicines, and the FDA has not reviewed their contents, purity or quality.
There are no controlled human trials of humanin, so there is no established safety profile. The FDA has not published a safety assessment of it. For other synthetic peptides it has reviewed, the agency has pointed to risks such as unwanted immune responses and peptide-related impurities.
Humanin is not named on the World Anti-Doping Agency (WADA) 2026 Prohibited List, which does name the related mitochondrial peptide MOTS-c. The list's S0 class covers any pharmacological substance not addressed elsewhere on the list that has no current approval by any government health authority for human therapeutic use. Athletes should confirm the status of any substance with their anti-doping organization.
Peptide Labs does not sell this compound. This page is general information, not medical advice. We are not a pharmacy, we do not supply humanin, and we do not point readers to anyone who does.
For personal medical questions, including questions about healthy aging or memory, the right person to ask is a licensed healthcare provider.
See the full list of compound profiles in the Peptide Guide. Related profiles: MOTS-c, SS-31 (elamipretide) and FOXO4-DRI. You can also read what peptides are.